Abstract:Hypertension is an independent risk factor for stroke. Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptor-dependent transcription factors. PPAR agonist fenofibrate has been shown to abrogate increased arterial prepro-endothelin-1 (preproET-1) and superoxide levels in deoxycorticosterone acetate (DOCA)-salt hypertension with unknown mechanism(s). We have reported that ET-1 induces endothelial dysfunction in the carotid arteries via NADPH oxidase-derived superoxide in this low renin hypertension model. Therefore, the present study tested the hypothesis that chronic PPAR activation in vivo reduces blood pressure and endothelial dysfunction via impeding cerebrovascular NADPH oxidase/superoxide and augmenting eNOS cofactor tetrahydrobiopterin (BH4) in DOCA-salt rats. DOCA-salt or sham-operated adult male rats were treated with fenofibrate (150 mg/kg/day) for 4 weeks beginning with DOCA-salt regimen. Oxidative stress markers and endothelial function were determined in the carotid arteries afterwards. Average systolic blood pressure was significantly increased in DOCA-salt rats (1868 vs. 1223 mmHg, DOCA vs. sham), which was blunted by fenofibrate (1868 vs. 1396 mmHg, DOCA vs. DOCA+PPAR, all n=11–16, p<0.01). Concomitantly, treatment with fenofibrate significantly reduced arterial NADPH oxidase activity (44.24.2 vs. 21.61.7 nmol/min/mg tissue DOCA vs. DOCA+PPAR), superoxide level (0.620.04 vs. 0.370.04 nmol/min/mg protein), VCAM-1 expression (0.460.07 vs. 0.280.04, VCAM-1/actin ratio, all n=5–10, p<0.05) and serum lipid peroxidation (TBAR 1.920.08 vs. 5.181.9 mol/L, n=10, p<0.01). Furthermore, treatment with fenofibrate significantly augmented arterial BH4 level (1.230.21 vs. 3.210.88 pmol/mg protein, n=7–8, p<0.05) and endogenous eNOS activity (6.000.40 vs. 12.961.61 nmol/mg protein, DOCA vs. DOCA+PPAR, n=8-9, p<0.05), resulting in improved endothelium-dependent NO-mediated relaxation in response to acetylcholine (39.732.98 vs. 78.313.83%, DOCA vs. DOCA+PPAR, n=9–10, p<0.05). These findings indicate that in vivo PPARá activation prevents progression of hypertension and reduces cerebrovascular endothelial dysfunction via impeding arterial NADPH oxidase-derived superoxide and augmenting eNOS essential cofactor BH4 in low renin mineralocorticoid hypertension. (Supported by American Heart Association grants 0130537Z and 0455594Z (to AFC), China Medical Board (CMB) grant 00730 and the National Natural Sciences Foundation of China grants 39940012 and 30271485 (to JSZ).

[Agonist-Induced Down-Regulation of Hepatic Glucocorticoid Receptor Via Peroxisome Proliferator-Activated Receptor in SD Rats].

Peroxisome proliferator-activated receptor α agonist-induced down-regulation of hepatic glucocorticoid receptor expression in SD rats

Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor α agonists

PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats]

Adipocyte-derived Periostin Mediates Glucocorticoid-Induced Hepatosteatosis in Mice

Interactions Between Nuclear Receptors Glucocorticoid Receptor Α and Peroxisome Proliferator–activated Receptor Α Form a Negative Feedback Loop

Fenofibrate Enhances the in Vitro Differentiation of Foxp3+ Regulatory T Cells in Mice

Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver

Upregulation of Hepatic VLDLR Via PPARα is Required for the Triglyceride-Lowering Effect of Fenofibrate.

Effects and mechanisms of PPARalpha activator fenofibrate on myocardial remodelling in hypertension.

Upregulation of Hepatic CD36 Via Glucocorticoid Receptor Activation Contributes to Dexamethasone-Induced Liver Lipid Metabolism Disorder in Mice.

PPARα Agonist Fenofibrate Attenuates TNF-α-induced CD40 Expression in 3T3-L1 Adipocytes Via the SIRT1-dependent Signaling Pathway

The Up-regulation of Palmitic Acids at High Concentrations to Expression of Subgroup α of Glucocorticoid Receptor

In vivo PPAR|[alpha]| activation attenuates cerebrovascular endothelial dysfunction via impeding NADPH oxidase-derived superoxide and augmenting tetrahydrobiopterin in mineralocorticoid hypertension

The GR-gp78 Pathway is Involved in Hepatic Lipid Accumulation Induced by Overexpression of 11Β-Hsd1

Effects of Fenofibrate on the Expressions of PPAR-γ,LXR Α and ABCA1 Mrna in Rats Model with Hyperlipaemia

Effects of TNF-α and IL-1 on Expression and Function of Glucocorticoid Receptor in Rat Hepatocytes in Vitro

Fenofibrate Ameliorates Cardiac Hypertrophy by Activation of Peroxisome Proliferator-Activated Receptor-Α Partly Via Preventing P65-Nfκb Binding to NFATc4.

Liver-specific Glucocorticoid Action in Alcoholic Liver Disease: Study of Glucocorticoid Receptor Knockout and Knockin Mice

Reduction of hepatic glucocorticoid receptor and hexose-6-phosphate dehydrogenase expression ameliorates diet-induced obesity and insulin resistance in mice.

Glucocorticoids promote hepatic cholestasis in mice by inhibiting the transcriptional activity of the farnesoid X receptor.